Atrasentan in Patients with IgA Nephropathy In the phase 3 ALIGN trial, the selective endothelin type A receptor antagonist atrasentan produced a clinically meaningful, statistically significant reduction in proteinuria versus placebo in patients with IgA nephropathy at high risk of progression.
More from ASNRT News Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.
All news · ASNRT home
Arab Society of Nephrology and Renal Transplantation
The Arab Society of Nephrology and Renal Transplantation (ASNRT) is a non-profit scientific society founded in 1985, advancing kidney care across 22 Arab countries through research, education, and clinical practice. The society operates through specialized committees, biannual congresses, the Arab Journal of Nephrology and Transplantation (AJNT), and a network of partner societies including the International Society of Nephrology (ISN), African Federation of Nephrology (AFRAN), and the International Society for Peritoneal Dialysis (ISPD).
Email: [email protected]
Languages: English, العربية